SNG — Synairgen Share Price
Last trade - 00:00- £11.66m
- -£2.97m
- 15
- 35
- 37
- 17
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.73 | ||
| Price to Tang. Book | 0.73 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -73.95% | ||
| Return on Equity | -48.86% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 0.1 | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.
Directors
- Simon James Blouet Shaw NEC
- John Ward CFO
- Phillip Monk CSO
- Richard Marsden MDR
- Gareth Walters OTH
- Iain Peter Murray Buchanan NED
- Bruce Campbell NED
- Sir Stephen Holgate NED
- Theodora Harold NID (47)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- September 16th, 2004
- Public Since
- October 26th, 2004
- No. of Employees
- 30
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 201,374,975
- Address
- Southampton General Hosp, Tremona Road, SOUTHAMPTON, SO16 6YD
- Web
- https://www.synairgen.com/
- Phone
- +44 2380512800
- Auditors
- BDO LLP
Latest News for SNG
Upcoming Events for SNG
Full Year 2023 Synairgen PLC Earnings Release
Synairgen PLC Annual Shareholders Meeting
Half Year 2024 Synairgen PLC Earnings Release
Similar to SNG
4Basebio
London Stock Exchange
Allergy Therapeutics
London Stock Exchange
Arecor Therapeutics
London Stock Exchange
Avacta
London Stock Exchange
Batm Advanced Communications
London Stock Exchange
FAQ
As of Today at 23:35 UTC, shares in Synairgen are trading at 5.79p. This share price information is delayed by 15 minutes.
Shares in Synairgen last closed at 5.79p and the price had moved by -22.8% over the past 365 days. In terms of relative price strength the Synairgen share price has underperformed the FTSE All Share Index by -27.5% over the past year.
The overall consensus recommendation for Synairgen is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Synairgen does not currently pay a dividend.
Synairgen does not currently pay a dividend.
Synairgen does not currently pay a dividend.
To buy shares in Synairgen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 5.79p, shares in Synairgen had a market capitalisation of £11.66m.
Here are the trading details for Synairgen:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: SNG
Based on an overall assessment of its quality, value and momentum Synairgen is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Synairgen is 8.00p. That is 38.17% above the last closing price of 5.79p.
Analysts covering Synairgen currently have a consensus Earnings Per Share (EPS) forecast of -£0.05 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Synairgen. Over the past six months, its share price has underperformed the FTSE All Share Index by -26.6%.
As of the last closing price of 5.79p, shares in Synairgen were trading -11.82% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Synairgen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 5.79p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Synairgen's management team is headed by:
- Simon James Blouet Shaw - NEC
- John Ward - CFO
- Phillip Monk - CSO
- Richard Marsden - MDR
- Gareth Walters - OTH
- Iain Peter Murray Buchanan - NED
- Bruce Campbell - NED
- Sir Stephen Holgate - NED
- Theodora Harold - NID